Panacea Biotech To Market Anthrax Vaccine

by Medindia Content Team on  December 29, 2001 at 2:23 PM Drug News
RSS Email Print This Page Comment
Font : A-A+

Panacea Biotech To Market Anthrax Vaccine
Panacea Biotech has bagged the registration, production and marketing rights of the anti-anthrax vaccine developed by the Centre for Biotechnology in the Jawaharlal Nehru University (JNU). It is expected that the vaccine would be in the market in 3-4 months. The Company has made a milestone payment to JNU for the exclusive rights. In addition, it will pay the university a royalty on sales. However, the company is yet to make any projections on the business the vaccine is expected to generate.

The vaccine is different from drugs such as ciprofloxacin currently being used in the treatment of anthrax. Ciprofloxacin is administered after a person has contacted anthrax. The vaccine develops immunity in the human body to anthrax bacillus. According to marketing director Rajesh, the vaccine developed by JNU is superior to the only other anti-anthrax vaccine available in the US. The vaccine in the US has a lot of toxic side- effects. The side-effect profile of this (JNU) vaccine is negligible. As anthrax has become a national emergency, the government's policy of fast-track registration will come into effect. This, in turn, will lead to a speedy commercialisation of the vaccine.


Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
Notify me when reply is posted
I agree to the terms and conditions

More News on:

Anthrax Bioterrorism 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive